JP2023518707A5 - - Google Patents
Info
- Publication number
- JP2023518707A5 JP2023518707A5 JP2022554548A JP2022554548A JP2023518707A5 JP 2023518707 A5 JP2023518707 A5 JP 2023518707A5 JP 2022554548 A JP2022554548 A JP 2022554548A JP 2022554548 A JP2022554548 A JP 2022554548A JP 2023518707 A5 JP2023518707 A5 JP 2023518707A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- patient
- wandering
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062994527P | 2020-03-25 | 2020-03-25 | |
| US62/994,527 | 2020-03-25 | ||
| US202063005913P | 2020-04-06 | 2020-04-06 | |
| US63/005,913 | 2020-04-06 | ||
| PCT/US2021/012587 WO2021194608A1 (en) | 2020-03-25 | 2021-01-08 | Methods of treating proteinopathy- associated wandering |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518707A JP2023518707A (ja) | 2023-05-08 |
| JP2023518707A5 true JP2023518707A5 (cg-RX-API-DMAC10.html) | 2024-01-16 |
Family
ID=77855102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554548A Pending JP2023518707A (ja) | 2020-03-25 | 2021-01-08 | タンパク質症に関連する徘徊を治療する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11642352B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4125879A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023518707A (cg-RX-API-DMAC10.html) |
| CN (1) | CN115916187A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3170073A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2022011518A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021194608A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021142183A1 (en) * | 2020-01-09 | 2021-07-15 | Woolsey Pharmaceuticals, Inc | Methods of treating cortical dementia associated wandering |
| US12329761B2 (en) | 2020-04-23 | 2025-06-17 | Woolsey Pharmaceuticals, Inc. | Methods of using rho kinase inhibitors to treat alzheimer's disease |
| EP4181925A4 (en) * | 2020-07-14 | 2024-07-31 | Woolsey Pharmaceuticals, Inc. | METHODS OF TREATMENT OF PROTEINOPATHIES |
| CA3231484A1 (en) | 2021-10-01 | 2023-04-06 | Qinwen Mao | Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy |
| CA3236338A1 (en) * | 2021-11-12 | 2023-05-19 | Woolsey Pharmaceuticals, Inc. | Method of treating amyotrophic lateral sclerosis and dosing regimen for same |
| WO2023097151A1 (en) | 2021-11-29 | 2023-06-01 | Woolsey Pharmaceuticals, Inc. | Methods of treating agitation and other dementia-associated behavioral symptoms |
| MX2024009983A (es) * | 2022-02-17 | 2024-08-26 | Woolsey Pharmaceuticals Inc | Formulaciones orales de fasudil que enmascaran el sabor. |
| MX2024010030A (es) * | 2022-02-17 | 2024-09-24 | Woolsey Pharmaceuticals Inc | Formulaciones orales de fasudil con resina de intercambio ionico. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3464012B2 (ja) | 1993-04-05 | 2003-11-05 | 旭化成株式会社 | 精神症候治療剤 |
| WO2000009133A1 (fr) * | 1998-08-10 | 2000-02-24 | Asahi Kasei Kogyo Kabushiki Kaisha | Preparations orales, a liberation prolongee, a base de chlorhydrate de fasudil |
| WO2005117896A1 (de) | 2004-06-03 | 2005-12-15 | Schering Aktiengesellschaft | Formulierungen, die fasudil, eine matrix und einem mantel enthalten |
| US20090318485A1 (en) * | 2006-07-20 | 2009-12-24 | Kalypsys, Inc. | Novel inhibitors of rho kinase |
| EP2061314A4 (en) | 2006-08-10 | 2010-08-04 | Translational Genomics Res Inst | CONNECTIONS TO IMPROVE LEARNING AND MEMORY |
| US20080044390A1 (en) | 2006-08-11 | 2008-02-21 | Xiaowei Jin | Methods and compositions for the treatment of neurodegenerative disorders |
| US20110237600A1 (en) | 2008-05-12 | 2011-09-29 | Amnestix, Inc. | Compounds for improving learning and memory |
| CN101612157A (zh) | 2008-06-26 | 2009-12-30 | 天津红日药业股份有限公司 | 法舒地尔诱导成年脑内源性神经干细胞再生的用途 |
| US20120010196A1 (en) * | 2010-04-02 | 2012-01-12 | Qin Quingyu | Methods of treating neurodegenerative disorders and diseases |
| EP2825175B1 (en) | 2012-03-12 | 2017-07-26 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis |
| WO2017195224A1 (en) | 2016-05-09 | 2017-11-16 | Istituto Superiore Di Sanita' | Rho gtpase activating bacterial toxins for use in the treatment of disorders of the central nervous system by mucosal administration |
| WO2021142183A1 (en) * | 2020-01-09 | 2021-07-15 | Woolsey Pharmaceuticals, Inc | Methods of treating cortical dementia associated wandering |
| US12329761B2 (en) * | 2020-04-23 | 2025-06-17 | Woolsey Pharmaceuticals, Inc. | Methods of using rho kinase inhibitors to treat alzheimer's disease |
| EP4181925A4 (en) * | 2020-07-14 | 2024-07-31 | Woolsey Pharmaceuticals, Inc. | METHODS OF TREATMENT OF PROTEINOPATHIES |
-
2021
- 2021-01-08 US US17/144,802 patent/US11642352B2/en active Active
- 2021-01-08 CA CA3170073A patent/CA3170073A1/en active Pending
- 2021-01-08 WO PCT/US2021/012587 patent/WO2021194608A1/en not_active Ceased
- 2021-01-08 CN CN202180036165.2A patent/CN115916187A/zh active Pending
- 2021-01-08 EP EP21776897.7A patent/EP4125879A4/en not_active Withdrawn
- 2021-01-08 JP JP2022554548A patent/JP2023518707A/ja active Pending
- 2021-01-08 MX MX2022011518A patent/MX2022011518A/es unknown
-
2023
- 2023-03-24 US US18/189,478 patent/US20230226073A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2224917T3 (en) | Composition with nicotine and opipramol and its use | |
| KR100566701B1 (ko) | 고위험의 내당력 장애를 치료하기 위한 알파-글루코시다제억제제의 용도 | |
| JP5792061B2 (ja) | 神経及び精神障害の治療法 | |
| US11318144B2 (en) | Compositions and methods for treating Alzheimer's disease and Parkinson's disease | |
| EP3813816B1 (en) | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome | |
| KR102059027B1 (ko) | Hdac6 억제제를 유효성분으로 포함하는 가려움증 예방 또는 치료용 약제학적 조성물 | |
| JP2002524498A (ja) | 機能性及び／又は器質性痛み症候群の治療のための製薬組成物の調製のためのアセチルコリンエステラーゼ阻害剤の使用 | |
| US6075028A (en) | Method of treating Tourette's syndrome and related CNS disorders | |
| US8802143B2 (en) | Method for treating neurodegenerative disorders with oral dosage formulation containing both immediate-release and sustained-release drugs | |
| JP2019501207A (ja) | バレニクリンまたはこの薬学的に許容可能な塩を含有する、味の遮蔽された口腔投与用薬学製剤 | |
| CA3183560A1 (en) | Compositions and methods for treating alzheimer's disease and parkinson's disease | |
| CA2985305C (en) | Combinations of opioids and n-acylethanolamines | |
| JP2024544500A5 (cg-RX-API-DMAC10.html) | ||
| CN110585226B (zh) | 金线莲苷在制备改善认知功能障碍的药物中的用途 | |
| TWI439269B (zh) | ４－環丙基甲氧基－ｎ－（３，５－二氯－１－氧離子基吡啶－４－基）－５－（甲氧基）吡啶－２－甲醯胺於製備用於治療與帕金森氏病有關之運動障礙症的藥物之用途 | |
| UA81052C2 (en) | Use of bicyclo [2.2.1] heptane derivatives for the preparation of neuroprotective pharmaceutical compositions for the reduction of the consequences of ischemic or traumatic brain and spinal damage | |
| WO2012129759A1 (en) | Oral dosage formulations containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders | |
| JPH07507280A (ja) | （−）−メトリフォネート含有薬剤 | |
| KR101503782B1 (ko) | 신경 세포사 억제제 | |
| CN121868499A (zh) | 一种预防或治疗神经系统变性疾病的方法和药物组合 | |
| HK40093852A (en) | Combinations of opioids and n-acylethanolamines | |
| JP2009501205A (ja) | 精神病治療用組成物 | |
| JP2004531480A (ja) | 神経変性疾患の処置のためのトリペプチド誘導体 | |
| HK40050398A (en) | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome | |
| HK40050398B (en) | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome |